Free tool
FAERS Monitor: Eurax
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 006927 or its brand name (Eurax, Crotamiton). Reports on generic versions are filed under their own applications.
Reports
610
Serious
577
95% of reports
Hospitalization
261
Death reported
79
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus61
- rash44
- pyrexia31
- malaise27
- anaemia26
- pain26
- hepatic function abnormal25
- pneumonia23
- diarrhoea21
- erythema21
- urticaria20
- decreased appetite19
- rash pruritic19
- vomiting19
- constipation18
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 14 |
| 2007 | 19 |
| 2008 | 16 |
| 2009 | 18 |
| 2010 | 26 |
| 2011 | 20 |
| 2012 | 41 |
| 2013 | 17 |
| 2014 | 28 |
| 2015 | 46 |
| 2016 | 31 |
| 2017 | 59 |
| 2018 | 36 |
| 2019 | 30 |
| 2020 | 32 |
| 2021 | 44 |
| 2022 | 27 |
| 2023 | 25 |
| 2024 | 32 |
| 2025 | 32 |
| 2026 | 12 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,549 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatic function abnormalSignal | 25 | 23.1 | 15.7 | 508 |
| rash pruriticSignal | 19 | 12.1 | 7.8 | 183 |
| pruritusSignal | 61 | 5.5 | 4.3 | 223 |
| anaemiaSignal | 26 | 4.7 | 3.2 | 73 |
| urticariaSignal | 20 | 4.1 | 2.7 | 44 |
| erythemaSignal | 21 | 3.5 | 2.3 | 36 |
| rashSignal | 44 | 3.5 | 2.6 | 77 |
| pyrexiaSignal | 31 | 3.1 | 2.2 | 42 |
| constipationSignal | 18 | 2.8 | 1.8 | 20 |
| decreased appetiteSignal | 19 | 2.8 | 1.8 | 21 |
| pneumoniaSignal | 23 | 2.4 | 1.6 | 19 |
| malaiseSignal | 27 | 2.1 | 1.5 | 15 |
| pain | 26 | 1.5 | 1.0 | 3 |
| vomiting | 19 | 1.4 | 0.9 | 2 |
| diarrhoea | 21 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.